Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP?T vaccination at 2, 4 and 6 months.

ABSTRACT: OBJECTIVE:To evaluate the long-term persistence of anti-hepatitis B surface (HBs) antibodies and the response to a HB challenge re-vaccination in children who had received a primary series of DTaP-IPV-HB-PRP?T (Hexaxim™) or DTaP-IPV-HB/PRP?T (Infanrix hexa™). METHODS:Two cohorts of participants who had previously received HB vaccine at birth followed by either DTaP-IPV-HB-PRP?T or DTaP-IPV-HB/PRP?T co-administered with PCV7 at 2, 4, 6 months of age in a randomized, Phase III, observer-blind study in Thailand, were followed up for anti-HBs antibodies (geometric mean concentrations [GMCs] and seroprotection [SP] rate [% of participants with a titer ?10 mIU/mL]) at 12-18 months of age and 9-10 years of age. A monovalent HB challenge re-vaccination was administered at 9-10 years of age and the anamnestic response was evaluated. RESULTS:Anti-HBs GMCs and SP rates in the DTaP-IPV-HB-PRP?T and DTaP-IPV-HB/PRP?T groups were high and similar post-primary vaccination series (2477 mIU/mL and 99.5% and 2442 mIU/mL and 99.5%, respectively) and declined to a similar extent in each group at 12-18 months (154.5 mIU/mL and 90.8% and 162.3 mIU/mL and 96.5%, respectively). Antibody levels further declined at 9-10 years of age (13.3 mIU/mL and 49.3% and 8.0 mIU/mL and 42.9%) and a strong anamnestic response occurred in each group post-HB challenge re-vaccination (92.8% and 98.7%, respectively). CONCLUSION:The kinetics of long-term anti-HBs antibody persistence were similar following a primary series of DTaP-IPV-HB-PRP?T or DTaP-IPV-HB/PRP?T. The response to a subsequent HB challenge re-vaccination was strong and similar in each group, demonstrating persisting immune memory.

SUBMITTER: Kosalaraksa P 

PROVIDER: S-EPMC5989896 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature